Skip to main content

Gain Therapeutics Inc (GANX) Stock

Gain Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Gain Therapeutics Inc (GANX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $2.52. Over the past 52 weeks, it has ranged between $1.41 and $4.34. This places the current price at 58.1% of its 52-week high and 78.7% above its 52-week low. Recent trading volume was recorded at 558,824. The 14-day Relative Strength Index (RSI) stands at 64.18, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $2.33 by 8.15%. Similarly, it is above its 200-day moving average of $2.11 by 19.43%. The MACD histogram is 0.13, indicating bullish momentum (MACD Line: 0.07, Signal Line: -0.05).

52-Week Range

$4.34 - $1.41

-41.94% from high · +78.72% from low

Avg Daily Volume

673,670

20-day average

100-day avg: 1,231,367

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

15.78

EV/EBITDA

-1.55

EPS (TTM)

-$0.61

Price to Sales

255.50

Beta

-0.02

Less volatile than market

Q:How is GANX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is GANX's risk profile compared to the market?
With a beta of -0.02, Gain Therapeutics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 15.78 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-17,553,668

Return on Equity

-261.70%

Return on Assets

-86.80%

Revenue Growth (YoY)

-100.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is GANX's business model?
Profitability metrics are not available for this stock.
Q:What are GANX's recent growth trends?
Gain Therapeutics Inc's revenue declined by 100.00% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$93.5M

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

38.46M

Book Value/Share

$0.16

Asset Type

Common Stock

Q:What is GANX's market capitalization and position?
Gain Therapeutics Inc has a market capitalization of $93.5M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 38.46M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does GANX's price compare to its book value?
Gain Therapeutics Inc's book value per share is $0.16, while the current stock price is $2.52, resulting in a price-to-book (P/B) ratio of 15.37. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$7.60

201.59% upside potential

Analyst Recommendations

Strong Buy

1

Buy

4

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for GANX?
5 analysts cover GANX with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $7.60 implies 201.6% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on GANX?
Current analyst recommendations:1 Strong Buy, 4 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:27 AM

Technical Indicators

RSI (14-day)

64.18

Neutral

50-Day Moving Average

$2.33

8.15% above MA-50

200-Day Moving Average

$2.11

19.43% above MA-200

MACD Line

0.07

MACD Signal

-0.05

MACD Histogram

0.13

Bullish

Q:What does GANX's RSI value tell investors?
The RSI (Relative Strength Index) for GANX is currently 64.18, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret GANX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.07 above the signal line at -0.05, with histogram at 0.13. This bullish crossover suggests upward momentum is building. The 50-day MA ($2.33) is above the 200-day MA ($2.11), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Feb 28, 2026, 12:33 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for GANX and get notified when the price changes.

Stay Ahead of the Market with Gain Therapeutics Inc Alerts

Set up price alerts for Gain Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.